<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093024</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0337</org_study_id>
    <secondary_id>2018-004530-14</secondary_id>
    <nct_id>NCT04093024</nct_id>
  </id_info>
  <brief_title>A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)</brief_title>
  <official_title>A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents (6 to 17 Year-old) With Clinically Significant Fibrosing Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate dose-exposure and safety of nintedanib in&#xD;
      children and adolescents with fibrosing Interstitial Lung Disease (ILD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">May 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Plasma Concentration-Time Curve at Steady State (AUCτ,ss) based on sampling at steady state (at week 2 and week 26);</measure>
    <time_frame>Week 2 and Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>N (%) of patients with treatment-emergent adverse events at week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>N (%) of patients with treatment-emergent pathological findings of epiphyseal growth plate on imaging at week 24, and week 52</measure>
    <time_frame>Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N (%) of patients with treatment-emergent pathological findings on dental examination or imaging at week 24, and week 52</measure>
    <time_frame>Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N (%) of patients with treatment-emergent adverse events over the whole trial</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height from baseline at week 24, week 52, week 76, and week 100</measure>
    <time_frame>Baseline, Week 24, Week 52, weeky 76, and week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC) % predicted from baseline at week 24, and week 52</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at week 24, and week 52</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen saturation (SpO2) on room air at rest from baseline at week 24, and week 52</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-min walk distance from baseline at week 24, and week 52</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient acceptability based on the size of capsules at week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient acceptability based on the number of capsules at week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first respiratory-related hospitalization over the whole trial</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first acute Interstitial Lung Disease (ILD) exacerbation or death over the whole trial</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death over the whole trial</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sitting height from baseline at week 24, week 52, week 76, and week 100</measure>
    <time_frame>Baseline, Week 24, Week 52, Week 76, and Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leg length from baseline at week 24, week 52, week 76, and week 100</measure>
    <time_frame>Baseline, Week 24, Week 52, Week 76, and Week 100</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Diseases, Interstitial</condition>
  <arm_group>
    <arm_group_label>Nintedanib (Ofev®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib (Ofev®)</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Nintedanib (Ofev®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children and adolescents 6 to 17 years old at Visit 2.&#xD;
&#xD;
          -  Signed and dated written informed consent and assent, where applicable, in accordance&#xD;
             with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and&#xD;
             local legislation prior to admission to the trial.&#xD;
&#xD;
          -  Male or female patients. Female of childbearing potential (WOCBP) must confirm that&#xD;
             sexual abstinence is standard practice and will be continued until 3 months after last&#xD;
             drug intake, or be ready and able to use a highly effective method of birth control&#xD;
             per International Conference on Harmonisation (ICH) M3 (R2) that results in a low&#xD;
             failure rate of less than 1% per year when used consistently and correctly, in&#xD;
             combination with one barrier method, from 28 days prior to initiation of study&#xD;
             treatment, during treatment and until 3 months after last drug intake. Sexual&#xD;
             abstinence is defined as abstinence from any sexual act that may result in pregnancy.&#xD;
             A list of contraception methods meeting these criteria is provided in the parental&#xD;
             information.&#xD;
&#xD;
          -  Patients with evidence of fibrosing Interstitial Lung Disease (ILD) on High-Resolution&#xD;
             Computed Tomography (HRCT) within 12 months of Visit 1 as assessed by the investigator&#xD;
             and confirmed by central review.&#xD;
&#xD;
          -  Patients with Forced Vital Capacity (FVC)% predicted ≥25% at Visit 2. [Note: Predicted&#xD;
             normal values will be calculated according to GLI (Global Lung Initiative)]&#xD;
&#xD;
          -  Patients with clinically significant disease at Visit 2, as assessed by the&#xD;
             investigator based on any of the following:&#xD;
&#xD;
               -  Fan score ≥3, or&#xD;
&#xD;
               -  Documented evidence of clinical progression over time based on either&#xD;
&#xD;
                    -  a 5-10% relative decline in FVC% predicted accompanied by worsening&#xD;
                       symptoms, or&#xD;
&#xD;
                    -  a ≥10% relative decline in FVC % predicted, or&#xD;
&#xD;
                    -  increased fibrosis on HRCT, or&#xD;
&#xD;
                    -  other measures of clinical worsening attributed to progressive lung disease&#xD;
                       (e.g. increased oxygen requirement, decreased diffusion capacity).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT)&gt;1.5 x Upper&#xD;
             Level of Normal (ULN) at Visit 1.&#xD;
&#xD;
          -  Bilirubin &gt;1.5 x ULN at Visit 1.&#xD;
&#xD;
          -  Creatinine clearance &lt;30 mL/min calculated by Schwartz formula at Visit 1. [Note:&#xD;
             Laboratory parameters from Visit 1 have to satisfy the laboratory threshold values as&#xD;
             shown above. Visit 2 laboratory results will be available only after randomization. In&#xD;
             case at Visit 2 the results do no longer satisfy the entry criteria, the Investigator&#xD;
             has to decide whether it is justified that the patient remains on study drug. The&#xD;
             justification for decision needs to be documented. Laboratory parameters that are&#xD;
             found to be abnormal at Visit 1 are allowed to be re-tested (once) if it is thought to&#xD;
             be a measurement error (i.e. there was no abnormal result of this test in the recent&#xD;
             history of the patient and there is no related clinical sign) or the result of a&#xD;
             temporary and reversible medical condition, once that condition is resolved.]&#xD;
&#xD;
          -  Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic&#xD;
             impairment) at Visit 1.&#xD;
&#xD;
          -  Previous treatment with nintedanib.&#xD;
&#xD;
          -  Other investigational therapy received within 1 month or 5 half-lives (whichever is&#xD;
             shorter but ≥1 week) prior to Visit 2.&#xD;
&#xD;
          -  Significant pulmonary arterial hypertension (PAH) defined by any of the following:&#xD;
&#xD;
               -  Previous clinical or echocardiographic evidence of significant right heart&#xD;
                  failure&#xD;
&#xD;
               -  History of right heart catheterization showing a cardiac index ≤2 l/min/m²&#xD;
&#xD;
               -  PAH requiring parenteral therapy with epoprostenol/treprostinil&#xD;
&#xD;
          -  In the opinion of the Investigator, other clinically significant pulmonary&#xD;
             abnormalities.&#xD;
&#xD;
          -  Cardiovascular diseases, any of the following:&#xD;
&#xD;
               -  Severe hypertension, uncontrolled under treatment, within 6 months of Visit 1.&#xD;
                  Uncontrolled hypertension is defined as&#xD;
&#xD;
                    -  In children 6 to ≤12 years old: ≥95th percentile + 12 mm Hg or ≥140/90 mm Hg&#xD;
                       (whichever is lower) (systolic or diastolic blood pressure equal to or&#xD;
                       greater than the calculated target value)&#xD;
&#xD;
                    -  In adolescents 13 to 17 years old: systolic blood pressure ≥140 mm Hg or&#xD;
                       diastolic blood pressure ≥90 mm Hg&#xD;
&#xD;
               -  Myocardial infarction within 6 months of Visit 1&#xD;
&#xD;
               -  Unstable cardiac angina within 6 months of Visit 1&#xD;
&#xD;
          -  Bleeding risk, any of the following:&#xD;
&#xD;
               -  Known genetic predisposition to bleeding&#xD;
&#xD;
               -  Patients who require&#xD;
&#xD;
                    -  Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K&#xD;
                       antagonists, direct thrombin inhibitors, heparin, hirudin)&#xD;
&#xD;
                    -  High dose antiplatelet therapy [Note: Prophylactic low dose heparin or&#xD;
                       heparin flush as needed for maintenance of an indwelling intravenous device&#xD;
                       (e.g. enoxaparin 4000 I.U. s.c. per day), as well as prophylactic use of&#xD;
                       antiplatelet therapy (e.g. acetyl salicylic acid up to 325 mg/day, or&#xD;
                       clopidogrel at 75 mg/day, or equivalent doses of other antiplatelet therapy)&#xD;
                       are not prohibited.]&#xD;
&#xD;
               -  History of haemorrhagic central nervous system (CNS) event within 12 months of&#xD;
                  Visit 1&#xD;
&#xD;
               -  Any of the following within 3 months of Visit 1:&#xD;
&#xD;
                    -  Haemoptysis or haematuria&#xD;
&#xD;
                    -  Active gastro-intestinal (GI) bleeding or GI - ulcers&#xD;
&#xD;
                    -  Major injury or surgery (investigator's judgment)&#xD;
&#xD;
               -  Any of the following coagulation parameters at Visit 1:&#xD;
&#xD;
                    -  International normalized ratio (INR) &gt;2&#xD;
&#xD;
                    -  Prolongation of prothrombin time (PT) by &gt;1.5 x ULN&#xD;
&#xD;
                    -  Prolongation of activated partial thromboplastin time (aPTT) by &gt;1.5 x ULN&#xD;
&#xD;
          -  History of thrombotic event (including stroke and transient ischemic attack) within 12&#xD;
             months of Visit 1.&#xD;
&#xD;
          -  Known hypersensitivity to the trial medication or its components (i.e. soya lecithin).&#xD;
&#xD;
          -  Patients with documented allergy to peanut or soya.&#xD;
&#xD;
          -  Other disease that may interfere with testing procedures or in the judgment of the&#xD;
             investigator may interfere with trial participation or may put the patient at risk&#xD;
             when participating in this trial.&#xD;
&#xD;
          -  Life expectancy for any concomitant disease other than Interstitial Lung Disease&#xD;
             (ILD)&lt;2.5 years (investigator assessment).&#xD;
&#xD;
          -  Female patients who are pregnant, nursing, or who plan to become pregnant while in the&#xD;
             trial.&#xD;
&#xD;
          -  Patients not able or willing to adhere to trial procedures, including intake of study&#xD;
             medication.&#xD;
&#xD;
          -  Patients with any diagnosed growth disorder such as growth hormone deficiency or any&#xD;
             genetic disorder that is associated with short stature (e.g. Turner Syndrome, Noonan&#xD;
             Syndrome, Russell-Silver Syndrome) and/or treatment with growth hormone therapy within&#xD;
             6 months before Visit 2. Patients with short stature considered by the investigator to&#xD;
             be due to glucocorticoid therapy may be included.&#xD;
&#xD;
          -  Patients &lt;13.5 kg of weight at Visit 1 (same threshold to be used for male and female&#xD;
             patients).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Kurland</last_name>
      <phone>+001 (412) 692-7060</phone>
      <email>Geoffrey.Kurland@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INSARES</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Elias</last_name>
      <phone>+54 261 4290628</phone>
      <email>carloselias@insares.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Tai</last_name>
      <phone>61 8 8161 9187</phone>
      <email>andrew.tai@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV HUDERF</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Lefèvre</last_name>
      <phone>+32 24773654</phone>
      <email>Nicolas.LEFEVRE@huderf.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Santa Maria</name>
      <address>
        <city>Barra Mansa</city>
        <zip>27323240</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GILMAR ZONZIN</last_name>
      <phone>55 24 981290844</phone>
      <email>gazonzin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Mitchell</last_name>
      <phone>403-955-2952</phone>
      <email>imitche@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital Motol, Oncology Clinic</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaclav Koucky</last_name>
      <phone>+420 224 434 700</phone>
      <email>vaclav.koucky@fnmotol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sune Rubak</last_name>
      <phone>+45 51729258</phone>
      <email>Sunerubak@skejby.rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sauli Palmu</last_name>
      <phone>358331166764</phone>
      <email>sauli.palmu@tuni.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Intercommunal</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Epaud</last_name>
      <phone>+33 (0)1 45 17 54 19</phone>
      <email>ralph.epaud@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamburger Zentrum für Kinder- und Jugendrheumatologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Foeldvari</last_name>
      <phone>+49 (40) 20923697</phone>
      <email>foeldvari@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;Ippokrateio&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Tsanakas</last_name>
      <phone>+302310992979</phone>
      <email>tsanakasj@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attila Szabo</last_name>
      <phone>+3613343743</phone>
      <email>szabo.attila@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osp. Pediatrico Bambin Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Cutrera</last_name>
      <phone>+39 (06) 68592372</phone>
      <email>renato.cutrera@opbg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr Jose Eleuterio Gonzalez</name>
      <address>
        <city>Nuevo León</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aquiles Quiroga Rivera</last_name>
      <phone>+52 81 8348 6173</phone>
      <email>aquirri2@yahoo.com.mx</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, Locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Terheggen-Lagro</last_name>
      <phone>+31 20 - 566 9111</phone>
      <email>s.w.terheggenlagro@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N-0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Håvard Ove Skjerven</last_name>
      <phone>+47 22118765</phone>
      <email>UXSKJH@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Children's Hospital</name>
      <address>
        <city>Warsaw</city>
        <zip>02091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Krenke</last_name>
      <phone>0048 22 3179419</phone>
      <email>katarzynakrenke@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHULN, EPE - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Bandeira</last_name>
      <phone>+351 217 805 000</phone>
      <email>terb@sapo.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hematology,Oncology&amp;Immunology na Rogachev,Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Shcherbina</last_name>
      <phone>+7 499 259 0151</phone>
      <email>shcher26@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Moreno Galdó</last_name>
      <phone>+34934893197</phone>
      <email>amoreno@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional clinical children hospital, Zaporizhya</name>
      <address>
        <city>Zaporizhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetyana Okul</last_name>
      <phone>+380 (61) 7646726</phone>
      <email>tanyapulmanolog@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children and Young People</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Cunningham</last_name>
      <phone>44(0)131 536 0641</phone>
      <email>Steve.Cunningham@ed.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

